Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01129050 · ClinicalTrials.gov registry record · NA

Effects of Omega-3 Fatty Acids on Markers of Inflammation

A NA study of Obesity and Hypertension, sponsored by Stanford University.

Completed
Registry status
NA
Development phase
102
Enrollment target
1
Study location

NCT01129050 is a NA study of Obesity and Hypertension that has completed, run by Stanford University. The registered enrollment target is 102 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01129050, a NA study of Obesity and Hypertension, has completed, sponsored by Stanford University.

COMPLETED
Registry status
NA
Development phase
102 participants
Enrollment target
1
Study location

Study Summary

The major purpose of this study is to examine the effect of two sources of dietary omega-3 fatty acids, each given at two doses, on potential health benefits related to cardiovascular disease prevention. The two sources of dietary omega-3 fatty acids will be fish oil, and flaxseed oil.

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Fish Oil
  • DIETARY_SUPPLEMENT Flaxseed Oil

Study Locations (1)

California

  • Stanford University School of Medicine - Stanford

Trial Details

FieldValue
Enrollment Target 102 participants
Start Date 2007-04
Est. Completion 2008-12
Phase NA

Sponsor

Stanford University

1,744 total trials

What the Registry Record Tells You About NCT01129050

The ClinicalTrials.gov registry entry for NCT01129050 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 102 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (88% lower). The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Obesity appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT01129050 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01129050 about?

NCT01129050 is a clinical study titled "Effects of Omega-3 Fatty Acids on Markers of Inflammation". The major purpose of this study is to examine the effect of two sources of dietary omega-3 fatty acids, each given at two doses, on potential health benefits related to cardiovascular disease prevention. The two sources of dietary omega-3 fatty acids will be fish oil, and flaxseed oil.

What is the current status of trial NCT01129050?

This trial is currently completed. It is a NA study. The enrollment target is 102 participants. The study started on 2007-04. Estimated completion is 2008-12.

What conditions does trial NCT01129050 study?

This clinical trial studies the following conditions: Obesity, Hypertension, Insulin Resistance, Hypertriglyceridemia.

What interventions are being tested in trial NCT01129050?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Fish Oil (DIETARY_SUPPLEMENT), Flaxseed Oil (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01129050?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01129050 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.